The triple reuptake inhibitor DOV216,303 exhibits limited antidepressant-like properties in the differential reinforcement of low-rate 72-second responding assay, likely due to dopamine reuptake inhibition

Journal of Psychopharmacology

Volumn 25, Issue 10, 2011, Pages 1357-1364

  Paterson, Neil E ^a   Balci, Fuat ^b   Campbell, Una ^c   Olivier, Berend E ^a,d   Hanania, Taleen ^a  

^a PSYCHOGENICS INC   (United States)

^b PRINCETON UNIVERSITY   (United States)

^c SUNOVION PHARMACEUTICALS INC   (United States)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Differential reinforcement of low rate (72 s) responding DOV216 303; dopamine; norepinephrine; predictive validity; rat; serotonin; triple reuptake inhibitor

Indexed keywords

AMFEBUTAMONE; AMITIFADINE; DESIPRAMINE; DIAZEPAM; DOPAMINE; DOPAMINE UPTAKE INHIBITOR; DOV 216313; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; NORADRENALIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG; VANOXERINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DIFFERENTIAL REINFORCEMENT OF LOW RATE 72 SECOND TEST; DOSE RESPONSE; DRUG ACTIVITY; DRUG MECHANISM; DRUG SCREENING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REINFORCEMENT; TASK PERFORMANCE;

ANIMALS; ANTIDEPRESSIVE AGENTS; AZA COMPOUNDS; BICYCLO COMPOUNDS, HETEROCYCLIC; BUPROPION; DESIPRAMINE; DIAZEPAM; DOPAMINE UPTAKE INHIBITORS; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; MALE; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; REINFORCEMENT (PSYCHOLOGY);

EID: 78649555631     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881110364272     Document Type: Article

References (45)

1. Andersen PH. The dopamine uptake inhibitor GBR12909: selectivity and molecular mechanism of action. Eur J Pharmacol. 1989 ; 166: 493-504 (Pubitemid 19195334)
2. Ardayfio PA, Benvenga MJ, Chaney SF, et al. The 5-hydroxytryptamine2A receptor antagonist R-(+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl-4-piperidinemethanol (M100907) attenuates impulsivity after both drug-induced disruption (dizocilpine) and enhancement (antidepressant drugs) of differential-reinforcement-of-low-rate 72-s behavior in the rat. J Pharmacol Exp Ther. 2008 ; 327: 891-897
3. Ascher JA, Cole JO, Colin JN, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry. 1995 ; 56: 395-401
4. Balcells-Olivero M, Richards JB, Seiden LS. Sensitization to amphetamine on the differential-reinforcement-of-low-rate 72-s schedule. Psychopharmacology (Berl). 1997 ; 133: 207-213 (Pubitemid 27445652)
5. Borsini F, Cesana R, Kelly J, et al. BIMT 17: a putative antidepressant with a fast onset of action?. Psychopharmacology (Berl). 1997 ; 134: 378-386 (Pubitemid 28023412)
6. Breuer ME, Chan JS, Oosting RS, et al. The triple monoaminergic reuptake inhibitor DOV 216,303 has antidepressant effects in the rat olfactory bulbectomy model and lacks sexual side effects. Eur Neuropsychopharmacol. 2008 ; 18: 908-916
7. Britton KT, Koob GF. Effects of corticotropin releasing factor, desipramine and haloperidol on a DRL schedule of reinforcement. Pharmacol Biochem Behav. 1989 ; 32: 967-970 (Pubitemid 19210285)
8. Claassen V, Davies JE, Hertting G, Placheta P. Fluvoxamine, a specific 5-hydroxytryptamine uptake inhibitor. Br J Pharmacol. 1977 ; 60: 505-516 (Pubitemid 8149535)
9. DeBattista C, Solvason HB, Poirier J, Kendrick E, Schatzberg AF. A prospective trial of bupropion SR augmentation of partial and non-responders to serotonergic antidepressants. J Clin Psychopharmacol. 2003 ; 23: 27-30 (Pubitemid 36164422)
10. Dekeyne A, Gobert A, Auclair A, Girardon S, Millan MJ. Differential modulation of efficiency in a food-rewarded "differential reinforcement of low-rate" 72-s schedule in rats by norepinephrine and serotonin reuptake inhibitors. Psychopharmacology (Berl). 2002 ; 162: 156-167 (Pubitemid 34743955)
11. Fowler SC, Pinkston J, Vorontsova E. Timing and space usage are disrupted by amphetamine in rats maintained on DRL 24-s and DRL 72-s schedules of reinforcement. Psychopharmacology (Berl). 2009 ; 204: 213-225
12. Howard JL, Pollard GT. Effects of imipramine, bupropion, chlorpromazine, and clozapine on differential-reinforcement-of-low-rate (DRL)>72-sec and >36-sec schedules in rat. Drug Dev Res. 1984 ; 4: 607-616 (Pubitemid 15207517)
13. Jackson A, Koek W, Colpaert FC. Can the DRL 72s schedule selectively reveal antidepressant drug activity?. Psychopharmacology (Berl). 1995 ; 117: 154-161
14. Kasper S, Fuger J, Möller HJ. Comparative efficacy of antidepressants. Drugs. 1992 ; 43 (Suppl 2). 11-22
15. Louis C, Cohen C, Depoortère R, Griebel G. Antidepressant-like effects of the corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, in a DRL-72 s schedule in the rat. Neuropsychopharmacology. 2006 ; 31: 2180-2187 (Pubitemid 44413195)
16. Machado-Vieira R, Salvadore G, Luckenbaugh DA, Manji HK, Zarate CA. Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry. 2008 ; 69: 946-958 (Pubitemid 351944948)
17. Marek GJ, Li AA, Seiden LS. Evidence for involvement of 5-hydroxytryptamine1 receptors in antidepressant-like drug effects on differential-reinforcement-of-low-rate 72-second behavior. J Pharmacol Exp Ther. 1989 ; 250: 60-71 (Pubitemid 19194974)
18. Marek GJ, Seiden LS. Selective inhibition of MAO-A, not MAO-B, results in antidepressant-like effects on DRL 72-s behavior. Psychopharmacology (Berl). 1988 ; 96: 153-160
19. McGuire PS, Seiden LS. Differential effects of imipramine in rats as a function of DRL schedule value. Pharmacol Biochem Behav. 1980 ; 13: 691-694 (Pubitemid 11253892)
20. Modell JG, Katholi CR, Modell JD, DePalma RL. Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline. Clin Pharmacol Ther. 1997 ; 61: 476-487 (Pubitemid 27195950)
21. Guide for the care and use of laboratory animals. Washington, DC: National Academy Press ; 1996 :
22. Nielsen JA, Shannon NJ, Bero L, Moore KE. Effects of acute and chronic bupropion on locomotor activity and dopaminergic neurons. Pharmacol Biochem Behav. 1986 ; 24: 795-799 (Pubitemid 16074746)
23. O'Donnell JM, Marek GJ, Seiden LS. Antidepressant effects assessed using behavior maintained under a differential-reinforcement-of-low-rate (DRL) operant schedule. Neurosci Biobehav Rev. 2005 ; 29: 785-798 (Pubitemid 40755464)
24. O'Donnell JM, Seiden LS. Effects of monoamine oxidase inhibitors on performance during differential reinforcement of low response rate. Psychopharmacology (Berl). 1982 ; 78: 214-218 (Pubitemid 13250845)
25. Olivier B, Bosch L, Van Hest A, et al. Preclinical evidence on the psychotropic profile of fluvoxamine. M Pharmacopsychiatry Suppl. 1993 ; 1: 2-9 (Pubitemid 23193092)
26. Pollard GT, Howard JL. Similar effects of antidepressant and non-antidepressant drugs on behavior under an interresponse-time greater than 72-s schedule. Psychopharmacology (Berl). 1986 ; 89: 253-258 (Pubitemid 16065508)
27. Richards JB, Sabol KE, Seiden LS. DRL interresponse-time distributions: quantification by peak deviation analysis. J Exp Anal Behav. 1993 ; 60: 361-385
28. Richards JB, Sabol KE, Hand TH, Jolly DC, Marek GJ, Seiden LS. Buspirone, gepirone, ipsapirone, and zalospirone have distinct effects on the differential-reinforcement-of-low-rate 72-s schedule when compared with 5-HTP and diazepam. Psychopharmacology (Berl). 1994 ; 114: 39-46 (Pubitemid 24150518)
29. Richards JB, Seiden LS. A quantitative interresponse-time analysis of DRL performance differentiates similar effects of the antidepressant desipramine and the novel anxiolytic gepirone. J Exp Anal Behav. 1991 ; 56: 173-192
30. Richelson E, Pfenning M. Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine release. Eur J Pharmacol. 1984 ; 104: 277-286 (Pubitemid 14006365)
31. Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol. 1999 ; 19: 67-85 (Pubitemid 29047334)
32. Seiden LS, Dahms JL, Shaughnessy RA. Behavioral screen for antidepressants: the effects of drugs and electroconvulsive shock on performance under a differential-reinforcement-of-low-rate schedule. Psychopharmacology (Berl). 1985 ; 86: 55-60 (Pubitemid 15075573)
33. Skolnick P, Krieter P, Tizzano J, et al. Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor. CNS Drug Rev. 2006 ; 12: 123-134 (Pubitemid 44300380)
34. Skolnick P, Popik P, Janowsky A, Beer B, Lippa AS. Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor. Eur J Pharmacol. 2003a ; 461: 99-104 (Pubitemid 36174028)
35. Skolnick P, Popik P, Janowsky A, Beer B, Lippa AS. "Broad spectrum" antidepressants: is more better for the treatment of depression?. Life Sci. 2003b ; 73: 3175-3179 (Pubitemid 37237572)
36. Sokolowski JD, Seiden LS. The behavioral effects of sertraline, fluoxetine, and paroxetine differ on the differential-reinforcement-of-low-rate 72-second operant schedule in the rat. Psychopharmacology (Berl). 1999 ; 147: 153-161 (Pubitemid 30010562)
37. Souery D, Amsterdam J, De Montigny C, et al. Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol. 1999 ; 9: 83-91 (Pubitemid 29073687)
38. Stahl SM, Grady MM, Moret C, Briley M. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr. 2005 ; 10: 732-747 (Pubitemid 41443048)
39. Suaud-Chagny MF, Dugast C, Chergui K, Msghina M, Gonon F. Uptake of dopamine released by impulse flow in the rat mesolimbic and striatal systems in vivo. J Neurochem. 1995 ; 65: 2603-2611
40. Thase ME, Clayton AH, Haight BR, Thompson AH, Modell JG, Johnston JA. A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability. J Clin Psychopharmacol. 2006 ; 26: 482-488 (Pubitemid 44401468)
41. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006 ; 354: 1243-1252
42. Van Hest A, Van Drimmelen M, Olivier B. Flesinoxan shows antidepressant activity in a DRL 72-s screen. Psychopharmacology (Berl). 1992 ; 107: 474-479
43. Wenger GR, Wright DW. Behavioral effects of cocaine and its interaction with d-amphetamine and morphine in rats. Pharmacol Biochem Behav. 1990 ; 35: 595-600 (Pubitemid 20115746)
44. Wong EH, Sonders MS, Amara SG, et al. Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol Psychiatry. 2000 ; 47: 818-929
45. Zhang HT, Whisler LR, Huang Y, Xiang Y, O'Donnell JM. Postsynaptic alpha-2 adrenergic receptors are critical for the antidepressant-like effects of desipramine on behavior. Neuropsychopharmacology. 2009 ; 34: 1067-1077